

2014 Update of the Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada Treatment Recommendations for the Management of Spondyloarthritis. Part II: Specific Management Recommendations

Sherry Rohekar, Jon Chan, Shirley M.L. Tse, Nigil Haroon, Vinod Chandran, Louis Bessette, Dianne Mosher, Cathy Flanagan, Kevin J. Keen, Karen Adams, Michael Mallinson, Carter Thorne, Proton Rahman, Dafna D. Gladman, and Robert D. Inman

ABSTRACT. Objective. The Canadian Rheumatology Association (CRA) and the Spondyloarthritis Research Consortium of Canada (SPARCC) have collaborated to update the recommendations for the management of spondyloarthritis (SpA).

Methods. A working group was assembled and consisted of the SPARCC executive committee, rheumatologist leaders from SPARCC collaborating sites, Canadian rheumatologists from across the country with an interest in SpA (both academic and community), a rheumatology trainee with an interest in SpA, an epidemiologist/health services researcher, a member of the CRA executive, a member of the CRA therapeutics committee, and a patient representative from the Canadian Spondylitis Association. An extensive review was conducted of literature published from 2007 to 2014 involving the management of SpA. The working group created draft recommendations using multiple rounds of Web-based surveys and an in-person conference.

Results. Recommendations for the management of SpA were created. Part II: Specific Management Recommendations addresses management with nonpharmacologic methods, nonsteroidal anti-inflammatory and analgesics, disease-modifying antirheumatic drugs, antibiotics, tumor necrosis factor inhibitors, other biologic agents, and surgery. Also included are 10 modifications for application to juvenile SpA.

Conclusion. These recommendations were developed based on current literature and applied to a Canadian healthcare context. It is hoped that implementation of these recommendations will promote best practices in the treatment of SpA. (First Release Feb 15 2015; J Rheumatol 2015;42:665–81; doi:10.3899/jrheum.141001)

Key Indexing Terms:

SPONDYLOARTHRITIS

ANKYLOSING SPONDYLITIS

PSORIATIC ARTHRITIS

From the University of Western Ontario, London; University of Toronto; The Hospital for Sick Children; Toronto Western Research Institute University Health Network; Division of Rheumatology, Department of Medicine, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital; Canadian Spondylitis Association, Toronto; University of Toronto, Southlake Regional Health Centre, Newmarket, Ontario, Canada; University of British Columbia, Vancouver; University of North British Columbia, Prince George, British Columbia; Laval University, Quebec City, Quebec; Department of Medicine, University of Calgary, Calgary, Alberta; Memorial University, St. John's, Newfoundland, Canada.

S. Rohekar, BSc, MD, FRCPC, MSc (Clin. Epi.), Associate Professor of Medicine, University of Western Ontario; J. Chan, BSc, MD, FRCPC; C. Flanagan, MDCM, Clinical Assistant Professor of Medicine, University of British Columbia; S.M. Tse, MD, FRCPC, Associate Professor of Medicine, University of Toronto, The Hospital for Sick Children; N. Haroon, MD, PhD, DM, Assistant Professor of Medicine, University of Toronto, Toronto Western Research Institute University Health Network; V. Chandran, MBBS, MD, DM, PhD, Assistant Professor of Medicine, University of Toronto, and Division of Rheumatology, Department of

Medicine, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital; L. Bessette, MD, MSc, FRCPC, Assistant Professor of Medicine; K. Adams, BSc, MD, FRCPC, Associate Professor of Medicine, Laval University; D. Mosher, MD, FRCPC, Professor of Medicine, Department of Medicine, University of Calgary; K.J. Keen, PhD, PStat, PStat(ASA), Associate Professor of Mathematics and Statistics, University of North British Columbia; M. Mallinson, BA, MA, President, Canadian Spondylitis Association; C. Thorne, MD, FRCPC Assistant Professor of Medicine, University of Toronto, Southlake Regional Health Centre; P. Rahman, MD, FRCPC, Associate Dean, Clinical Research and Professor of Medicine, Memorial University; D.D. Gladman, MD, Professor of Medicine, University of Toronto, and Senior Scientist, Toronto Western Research Institute, Centre for Prognosis Studies in The Rheumatic Diseases, Toronto Western Hospital; R.D. Inman, MD, Professor of Medicine and Immunology, University of Toronto, Toronto Western Research Institute.

Address correspondence to Dr. S. Rohekar, Division of Rheumatology, St. Joseph's Hospital, 268 Grosvenor St., London, Ontario N6A 4V2, Canada. E-mail: Sherry.rohekar@sjhc.london.on.ca

Accepted for publication December 22, 2014.

Personal non-commercial use only. The Journal of Rheumatology Copyright © 2015. All rights reserved.

To address rapid changes in spondyloarthritis (SpA) management, the Canadian Rheumatology Association (CRA)/Spondyloarthritis Research Consortium of Canada (SPARCC) presents the 2014 Update of the CRA/SPARCC Treatment Recommendations for the Management of Spondyloarthritis. We aim to inform best practices of the Canadian rheumatologists, primary care physicians, allied health professionals, patients, and policy makers.

These recommendations have been divided into 2 parts: (Part I) Principles of the Management of SpA, and (Part II) Specific Management Recommendations. Part I addresses optimal SpA management in Canada and has been presented previously, and the principles were largely derived from expert opinion¹. Part II contains specific recommendations for treatment with a larger body of literature support. Supplementary data are available online at jrheum.org.

Recommendations were based upon the highest quality of evidence available at the time of this review. They are intended to promote best practices and improve delivery of healthcare for those with SpA. Recommendations should not be interpreted as rigid or legal standards, nor are they intended to replace the clinical judgment of rheumatologists and other trained SpA healthcare providers acting according to the individual needs of the patient.

MATERIALS AND METHODS

Participants, patient population, scope, development process, evidence-based literature review, grading evidence, and extended review methodology have been described previously¹. Table 1 reviews levels of evidence (LOE) and strength of recommendation (SOR).

RESULTS

The CRA/SPARCC Specific Management Recommendations are summarized in Table 2. These recommendations may be applied to juvenile SpA (JSpA) enthesitis-related arthritis (ERA) through modifications (Table 3). The LOE, SOR, and expert opinion score (EO) are listed for each recommendation. EO was evaluated on a 5-point Likert

scale ranging from “disagree completely” to “agree completely”. Barriers to implementation of individual recommendations are also described. These address elements of the healthcare system that may affect the applicability of the recommendations.

Specific Management Recommendations Nonpharmacological

Recommendation 1. Treatment includes education, exercise, physical therapy (PT), and the involvement in patient associations. PT and exercise in ankylosing spondylitis (AS) have been the subject of systematic literature reviews, finding positive effects for both, with PT having the greatest effect (LOE I, SOR A)^{2,3}.

Systematic review of exercise in AS demonstrated small improvements in spinal mobility, but was limited by the poor quality of included studies (LOE II, SOR B)⁴.

Involvement in patient organizations is based upon expert opinion (LOE IV, SOR D).

Barriers to implementation include lack of reimbursement for services and geographical limitations to access.

Recommendation 2. Recommends smoking cessation. Smoking is associated with worse radiographic outcomes in axial SpA (axSpA); further, this relationship may be dose-dependent^{5,6}. Smoking has been associated with worse inflammation and radiographic damage in early axSpA, and with radiographic severity even in long-standing disease^{7,8}.

Smoking also harms patient outcomes, including the Bath Ankylosing Spondylitis Functional Index and functional status in both early and established SpA^{7,9,10,11,12,13,14}. Again, this relationship may be dose-dependent¹⁵. Smoking also limits function in psoriatic arthritis (PsA)¹⁶.

The LOE is II and SOR is B for smoking cessation in SpA.

There are no barriers to the implementation of smoking cessation recommendations.

Table 1. Custom system for assigning LOE and SOR.

LOE	SOR
I: Metaanalysis, systematic reviews of RCT, or an individual RCT	A: Strong recommendation: • Direct level 1 evidence
II: Metaanalysis, systematic reviews of observational studies (cohort/case control studies), or individual observational studies, OR RCT subgroup/posthoc analysis	B: Moderate recommendation: • Direct level 2 or extrapolated level 1 evidence
III: Nonanalytic studies (case reports, case series)	C: Weak recommendation: • Direct level 3 or extrapolated level 2 evidence
IV: Expert opinion	D: Consensus recommendation: • Expert opinion based on very little evidence
NR: Recommendation is not linked to evidence	

LOE: level of evidence; SOR: strength of recommendation; RCT: randomized controlled trial; NR: not reported.

Table 2. 2014 Update on the CRA/SPARCC Specific Treatment Recommendations for the Management of SpA.

Recommendation	LOE	SOR	EO
Nonpharmacological			
1. Nonpharmacological treatment of SpA should include patient education and regular exercise, preferably at centers of expertise or with experienced physiotherapists. Individual and group physical therapy should be considered. Patient associations and self-help groups may be useful.	I (physio) II (exercise) I (education) IV (self-help)	A (physio) B (exercise) A (education) D (self-help)	5.0
2. Smoking contributes to radiographic progression in axSpA, and smoking cessation should be recommended.	II	B	5.0
NSAID and analgesics			
3. NSAID are recommended as first-line drug treatment for symptomatic patients with axSpA. A sufficient trial of therapy is defined as at least 2 NSAID, each administered over a minimum 2-week period at the maximum tolerated dosage, unless contraindicated.	I	A	4.9
4. The decision to use NSAID should be made after considering the patient's cardiovascular risk factors. NSAID with the best cardiovascular safety profile should be preferred.	I	A	4.9
5. When there is no therapeutic advantage, selective COX-2 inhibitor therapy should be used in patients at increased risk for GI adverse events. In patients at risk who respond best to a traditional NSAID, a gastroprotective agent can be used.	I	A	4.7
6. Patients on longterm, regular NSAID therapy should be regularly monitored for changes in GI, cardiovascular, and renal status.	I	B	4.7
7. If NSAID are insufficient or contraindicated, alternative pain control strategies (i.e., acetaminophen, opioids) should be considered. It should be noted that non-NSAID analgesics do not control inflammation.	IV	D	4.9
Corticosteroids			
8. Corticosteroid injections at local sites of inflammation (i.e., SI joints, peripheral joints, and entheses) may be considered.	I (SI joints) II (PsA joint) IV (all other sites)	A (SI joints) B (PsA joint) D (all other sites)	4.7
9. Short courses of systemic corticosteroids may be considered for specific manifestations. The sustained use of systemic steroids is not recommended or supported.	I (AS) IV (other SpA)	A (AS) D (other SpA)	4.7
DMARD			
10. There is no evidence for the efficacy of DMARD, including SSZ and MTX, for the treatment of axSpA.	I	A	4.8
11. SSZ, MTX, and leflunomide may be considered in patients with peripheral SpA, but have only minimal to moderate evidence of efficacy. Dosing and monitoring of these drugs should be tailored to the individual patient and follow usual standard of care.	I	A	4.9
12. Combination therapy with DMARD should be considered in peripheral SpA, particularly in patients with poor prognostic features, moderate-high disease activity and in patients with recent-onset disease. Combination therapy should also be considered in patients with inadequate response to monotherapy.	IV	D	4.4
Antibiotics			
13. A trial of rifampin plus either doxycycline or azithromycin may be tried for 6 mos in cases of proven post- <i>Chlamydia</i> chronic reactive arthritis. There is no evidence of efficacy for antibiotics in axSpA.	IV	D	4.5
TNFi			
14. TNFi should be given only under supervision by a rheumatologist to patients with persistently high disease activity, despite other therapy. Routine laboratory screening (complete blood count, liver and renal function) as well as screening for Hepatitis B and C (and HIV in high risk patients) should be performed prior to initiation. Screening for latent TB infection should be performed prior to initiation. Baseline ANA may be considered. CRA recommendations for prevention of TB should be followed. Seasonal vaccination for influenza is recommended for patients before or during treatment with TNFi. Hepatitis B vaccine should be considered in high-risk groups in patients determined to be nonimmune to HBV. H. zoster vaccine should be considered in patients aged 60 yrs or older.	IV	D	4.9
15. There is no evidence to support the obligatory use of DMARD before, or concomitant with, TNFi in patients with axSpA.	I	A	4.8
16. For patients with predominantly axSpA, TNFi should be offered to those with persistent symptoms after a trial of NSAID therapy as defined above and evidence of active disease as defined by at least 2 of the following:			
<ul style="list-style-type: none"> • BASDAI > 4 • Elevated CRP or ESR • Inflammatory lesions in the SI joints and/or spine on MRI 	I (TNFi efficacy) IV (active disease definition)	A (TNFi efficacy) IV (active disease definition)	4.2

Table 2. Continued.

Recommendation	LOE	SOR	EO
17. For patients with predominantly peripheral SpA, TNF inhibitors should be offered to those with persistent inflammation despite a trial of NSAID as above and 1 DMARD.	I (TNFi efficacy) IV (post NSAID and DMARD)	A (TNFi efficacy) D (post NSAID and DMARD)	4.9
18. For patients with refractory enthesitis or dactylitis, TNFi should be offered to those with persistent inflammation.	I (enthesitis) II (dactylitis)	A (enthesitis) B (dactylitis)	4.5
19. Several TNFi are available for the treatment of SpA, including infliximab, etanercept, adalimumab, golimumab, and certolizumab. The choice of TNFi should be determined by consultation between the physician and patient. Dosing and monitoring of these drugs should be tailored to the individual patient and follow usual standard of care.	I	B	5.0
20. Maintenance on TNFi should be based on attainment of clinical response 16 weeks after initiating treatment. In axSpA, a clinical response is defined as either an absolute reduction of the BASDAI by 2 (0–10 scale) or a relative reduction of 50%. In peripheral SpA, a clinical response is defined as a reduction in active joint count by 30%.	IV	D	4.7
21. The choice of TNFi should incorporate the presence or absence of extraarticular manifestations. When possible, the chosen TNFi should treat both SpA and the particular extrarticular manifestations effectively.	I	A	4.9
22. Combination of MTX and TNFi does not influence clinical efficacy, though in peripheral SpA it may be associated with prolonged drug response.	II	B	4.5
23. Nonresponders to TNFi may benefit from switching to another TNFi.	II	B	4.9
Other biologic agents			
24. Rituximab may be considered for the treatment of axSpA for patients in whom TNFi are contraindicated.	II	B	4.2
25. Ustekinumab may be considered for the treatment of patients with SpA with concomitant moderate to severe cutaneous psoriasis.	I	A	4.8
26. There is currently no evidence for the use of other biologic agents in SpA, including ABA, TCZ, and anakinra.	II (ABA) I (TCZ) II (anakinra)	B (ABA) A (TCZ) B (anakinra)	4.9
Surgery			
27. Total hip arthroplasty should be considered in patients with refractory pain or disability and radiographic evidence of structural damage, independent of age.	II (axial) IV (peripheral)	B (axial) D (peripheral)	5.0
28. Spinal surgery, for example, corrective osteotomy and stabilization procedures, may be of value in selected patients, ideally at surgical centers with experience in AS spinal disease.	III	C	4.8

CRA: Canadian Rheumatology Association; SPARCC: Spondyloarthritis Research Consortium of Canada; SpA: spondyloarthritis; LOE: level of evidence; SOR: strength of recommendation; EO: expert opinion; axSpA: axial SpA; NSAID: nonsteroidal antiinflammatory drugs; COX-2: cyclooxygenase-2; GI: gastrointestinal; SI: sacroiliac; PsA: psoriatic arthritis; AS: ankylosing spondylitis; DMARD: disease-modifying antirheumatic drugs; SSZ: sulfasalazine; MTX: methotrexate; TNFi: tumor necrosis factor inhibitors; HIV: human immunodeficiency virus; TB: tuberculosis; ANA: antinuclear antibody; HBV: hepatitis B virus; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; MRI: magnetic resonance imaging; ABA: abatacept; TCZ: tocilizumab.

Nonsteroidal Antiinflammatory Drugs (NSAID) and Analgesics

Recommendation 3. NSAID are first-line drug treatments for symptomatic patients with axSpA. An appropriate trial consists of at least 2 NSAID, each administered over a minimum of 2 weeks at maximum tolerated dosage, unless contraindicated.

Several randomized controlled trials (RCT) and posthoc analyses have demonstrated NSAID efficacy in AS in the long and short terms^{17,18,19,20,21}. A metaanalysis of NSAID RCT showed a medium–large effect size for pain, function, and patient assessment of the disease²². NSAID may have the greatest effect in patients with AS who have elevated acute-phase reactants (APR)²³.

Continuous NSAID may modify radiographic outcome in AS. An RCT of continuous versus on-demand celecoxib found that continuous users had less radiographic progression, even after adjusting for confounders²⁴. Posthoc

analysis demonstrated that this effect was restricted to those with elevated APR²⁵. The German SPondyloarthritis Inception Cohort found no difference in radiographic progression with high NSAID intake overall, but less progression in those with baseline syndesmophytes and elevated C-reactive protein²⁶.

The LOE for Recommendation 3 is I and SOR is A.

There are no barriers to implementation of this recommendation.

Recommendations 4–6. Address potential toxicities and methods to minimize adverse events from NSAID use. A literature review for these recommendations is beyond this article’s scope, but are addressed in a 2008 review paper²⁷. The LOE and SOR for recommendations 4 and 5 are I and A, and for 6 they are I and B.

There are no barriers to the implementation of these recommendations.

Recommendation 7. Acetaminophen and opioids may be

Table 3. The 2014 Update on the CRA/SPARCC Treatment Recommendations for the Management of SpA for application to JSpA(ERA).

Recommendation	LOE	SOR
Nonpharmacological		
1. Children and adolescents with JIA have reduced aerobic fitness, but can participate in exercise without disease exacerbation. Patients with JSpA(ERA) should be strongly encouraged to participate in regular physical activities that are compatible with the child's general abilities and development.	I	B
2. Peripheral arthritis and enthesitis involving the foot and ankle are common in JSpA(ERA) and the use of comfortable, cushioning, and supportive foot orthotics should be considered in these patients.	I	B
NSAID and analgesics		
3. Peripheral SpA is more common in JSpA(ERA) and should be managed with an adequate trial of NSAID (1–2 mos) initially.	IV	D
4. Sacroiliitis in JSpA(ERA) can be managed according to the axSpA recommendations.	IV	D
Corticosteroids		
5. No specific modifications.	I	B
DMARD		
6. No specific modifications.	I (SSZ) III (MTX, LEF)	A (SSZ) C (MTX, LEF)
Antibiotics		
7. No specific modifications.	IV	D
TNFi		
8. TNFi are beneficial in JSpA(ERA) and should be prescribed in accordance to the predominantly axial or peripheral SpA recommendations. TNFi available for the treatment of JSpA(ERA) is currently restricted to ETN, ADA, and IFX.	I (IFX, ADA) II (ETN)	A (IFX, ADA) B (ETN)
Other biologic agents		
9. The use of these agents in JSpA(ERA) has not been studied.	IV	D
Surgery		
10. No specific modifications.	IV	D

CRA: Canadian Rheumatology Association; SPARCC: Spondyloarthritis Research Consortium of Canada; SpA: spondyloarthritis; JSpA: juvenile SpA; ERA: enthesitis-related arthritis; LOE: level of evidence; SOR: strength of recommendation; JIA: juvenile idiopathic arthritis; NSAID: nonsteroidal antiinflammatory drugs; axSpA: axial SpA; DMARD: disease-modifying antirheumatic drugs; SSZ: sulfasalazine; MTX: methotrexate; LEF: leflunomide; TNFi: tumor necrosis factor inhibitors; ETN: etanercept; ADA: adalimumab; IFX: infliximab.

tried in patients with otherwise uncontrolled pain. To our knowledge, no trials address this issue (LOE IV, SOR D).

There are no barriers to the implementation of this recommendation.

Corticosteroids

Recommendation 8. Consider corticosteroid injections at sites of inflammation, including sacroiliac (SI) joints, peripheral joints, and entheses. Placebo-controlled trials of radiographic-guided SI joint injections showed significant improvements in pain with minimal adverse events^{28,29,30,31,32}. One study was contradictory³³. Computed tomography-guided SI injection decreased magnetic resonance imaging (MRI) inflammation^{31,32}. Case series also supported SI joint injection^{28,34,35}. The LOE and SOR for SI joint injection are I and A.

One prospective cohort study of intraarticular steroid injection in PsA demonstrated good response at 3 months³⁶. No studies assessed intraarticular injections in other SpA, nor were there studies of enthesal injection. (LOE II, SOR B for intraarticular corticosteroid injection in PsA. LOE IV, SOR D for all other intraarticular or enthesal injections.)

A limitation to implementation of this recommendation is

the difficulty of accessing radiographic-guided SI joint injections.

Recommendation 9. Consider a short course of systemic corticosteroids for specific manifestations of SpA, though sustained use is discouraged. An RCT of oral steroids in NSAID-resistant AS found high-dose prednisolone over 2 weeks was effective³⁷. Interestingly, low-dose prednisolone was ineffective, contrary to prior practice of using steroid-responsiveness to discriminate mechanical from inflammatory back pain³⁷. Two additional small studies have supported the use of pulse methylprednisolone in NSAID nonresponders^{38,39}. Systemic corticosteroid use in PsA was historically discouraged owing to the concern of psoriasis flare, but low-dose corticosteroid use in PsA may be common⁴⁰. The LOE and SOR of a brief course of systemic steroids in AS are I and A; and for all other SpA, IV and D.

There are no barriers to the implementation of this recommendation.

Disease-modifying Antirheumatic Drugs (DMARD)

Recommendation 10. There is no evidence for DMARD efficacy in axSpA.

A systematic review of methotrexate (MTX) for AS concluded there was “no evidence to support any benefit of MTX in the treatment of AS”⁴¹.

Sulfasalazine (SSZ) use in AS was also reviewed, showing reduction of morning stiffness and erythrocyte sedimentation rate (ESR), but no effect on pain, function, mobility, or enthesitis^{42,43,44}. SSZ was compared head-to-head with etanercept (ETN) in the axSpA ASCEND (Ankylosing Spondylitis Study Comparing ENbrel and Sulfasalazine Dosed Weekly) and ESTHER (Enbrel Sulfasalazine Early Axial Spondyloarthritis) trials^{45,46}. Though SSZ did improve some axial symptoms, ETN produced significantly greater improvements than SSZ^{45,47}. ESTHER demonstrated that SSZ decreased MRI inflammation in axSpA, but minimally compared to ETN⁴⁶. These studies lacked placebo control, affecting the ability to derive decisive conclusions regarding SSZ effectiveness in axSpA.

Two studies showed that leflunomide (LEF) was ineffective in active AS^{48,49}.

Overall, Recommendation 10 is LOE I, SOR A.

There are no barriers to the implementation of this recommendation.

Recommendation 11. Addresses DMARD use in peripheral SpA based upon PsA data. DMARD use in PsA was recently extensively reviewed, and metaanalysis concluded that MTX was effective for peripheral arthritis⁵⁰. Significant improvements were found in joint counts^{51,52,53}, pain^{51,53}, and ESR^{52,53}. However, MTX did not affect radiographic progression⁵⁴. Subsequently, a double-blind, placebo-controlled RCT of MTX 15 mg/week showed that MTX did not improve joint counts, APR, or patient-reported outcomes (PRO)⁵⁵.

The above metaanalysis assessed SSZ use in peripheral PsA and found it to be effective, but minimally so⁵⁰. SSZ also did not prevent radiographic progression⁵⁶.

Effectiveness of LEF in PsA was also assessed⁵⁰. A placebo-controlled RCT found LEF useful for peripheral arthritis and psoriasis⁵⁷. Open trials have supported these results^{58,59}. An observational study showed that LEF improved joint counts, dactylitis, and PRO⁶⁰.

Overall, the LOE and SOR for the use of DMARD such as MTX, SSZ, and LEF in peripheral SpA (specifically peripheral PsA) are I and A. Our scoring metric assigns high levels to metaanalyses and RCT, regardless of potential flaws in study design. The effect of these DMARD, though positive, is clinically minimal.

Recommendation 12. Consider combination therapy with DMARD in peripheral SpA, particularly those with poor prognostic factors, greater disease activity, recent-onset disease, and monotherapy resistance (LOE IV, SOR D).

Recommendations 11 and 12 may be restricted in circumstances where patients have limited drug coverage.

Antibiotics

Recommendation 13. Consider testing antibiotics in post-*Chlamydia* chronic reactive arthritis (ReA). A review of antibiotics for ReA concluded that their effects were, in general, uncertain⁶¹. The regimen proposed for post-*Chlamydia* ReA is based upon 1 double-blind placebo-controlled trial. Followup studies to confirm these findings have not yet been performed. In view of the findings of the recent metaanalysis, the LOE is IV and the SOR for this recommendation is D⁶².

Significant barriers to implementation include often limited access to diagnosing physicians, and high drug costs.

Tumor Necrosis Factor Inhibitors (TNFi)

Recommendation 14. Addresses administration, monitoring, and preventive measures that are suggested when prescribing TNFi in SpA (LOE IV, SOR D).

There are no barriers to the implementation of this recommendation.

Recommendation 15. No evidence supports the DMARD use before or concomitant with TNFi in axSpA, as reviewed in Recommendation 12 (LOE I, SOR A).

There are no barriers to the implementation of this recommendation.

Recommendation 16. TNFi are efficacious for axSpA. This details the clinical characteristics of patients suitable for treatment. A metaanalysis encompassing 2005–2009 concluded that evidence for treatment with TNFi was very high, and found TNFi were similarly effective in nonradiographic axSpA and AS⁶³.

There has been extensive reporting of the effectiveness, safety, and reduction of MRI inflammation for each TNFi approved for axSpA in Canada: infliximab (IFX)^{64,65,66,67,68,69,70,71,72,73,74}, ETN^{45,46,75,76,77,78}, adalimumab (ADA)^{79,80,81,82,83,84,85,86,87,88,89}, golimumab (GOL)^{90,91,92,93,94}, and certolizumab pegol (CZP)^{95,96}.

A prospective study also suggested that earlier TNFi treatment in AS reduced radiographic progression⁵.

The LOE and SOR for TNFi in axSpA are I and A.

Recommendation 16 also states that TNFi should be offered to those with persistent active axSpA despite NSAID treatment. These recommendations define active axial disease as the presence of 2 of the following: Bath Ankylosing Spondylitis Disease Activity Index > 4, elevated APR, or the presence of inflammatory lesions in the SI joint and/or spine on MRI. This definition of active disease is based on expert consensus; therefore, this portion of Recommendation 16 has an LOE IV and SOR D.

The major barrier to the implementation of this recommendation is drug cost. Even those privately insured may face a large co-payment. Patients may face lengthy application processes for drug access.

Recommendation 17. For peripheral SpA, offer TNFi to those with persistent inflammation despite a trial of NSAID and 1 DMARD. This recommendation is derived from PsA literature.

A review of PsA literature up to July 2011 included studies of IFX, ETN, ADA, and GOL⁹⁷; all demonstrated TNFi efficacy in ACR composite outcomes and skin manifestations⁹⁷. No studies specifically addressed TNFi use in psoriatic oligoarthritis⁹⁷. A metaanalysis encompassing 1962–2010 and including studies of IFX, ETN, and ADA also supported these findings and demonstrated that TNFi repressed radiographic progression in PsA⁵⁰.

ADA has also been shown to improve outcomes in non-AS, non-PsA peripheral SpA⁹⁸.

TNFi use in peripheral SpA has an LOE I and SOR A. Recommendation 17 also advises that TNFi be used in those with persistent inflammation despite a trial of NSAID and 1 DMARD. This component of the recommendation is based on expert opinion (LOE IV, SOR D).

Cost remains the largest barrier to this recommendation's implementation. Some patients may endure severe disease while waiting to fulfill public reimbursement criteria.

Recommendation 18. Consider TNFi treatment for unresponsive enthesitis and dactylitis. Two studies found TNFi were efficacious for enthesitis^{99,100}. TNFi effect on enthesitis has been assessed as a secondary outcome by numerous PsA RCT, all demonstrating improvement⁹⁷. No RCT directly addresses dactylitis treatment with TNFi, but a cohort study of PsA showed that TNFi treatment may be a predictor of improvement¹⁰¹. Dactylitis is frequently a secondary outcome in PsA RCT of TNFi⁹⁷. IFX^{102,103}, ETN¹⁰⁴, ADA¹⁰⁵, GOL^{106,107}, and CZP¹⁰⁸ improved dactylitis. The LOE and SOR for TNFi for enthesitis are I and A; for dactylitis, II and B. Patient characteristics for TNFi treatment are based on expert opinion (LOE IV, SOR D).

The major barrier to implementation of this recommendation is cost.

Recommendation 19. Many TNFi are available, including IFX, ETN, ADA, GOL, and CZP. Choice of TNFi is based upon mutual understanding between physician and patient. There are no head-to-head trials of TNFi, but a similar study design in Phase III RCT supports comparable efficacy (LOE I, SOR B).

There are no barriers to the implementation of this recommendation.

Recommendation 20. Defines clinical response to TNFi in both axial and peripheral SpA. These recommendations are consistent with current recommendations from the Assessment of Spondyloarthritis International Society and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis, but are based on expert consensus (LOE IV, SOR D)^{21,109}.

There are no barriers to the implementation of this recommendation.

Recommendation 21. TNFi choice should incorporate treatment of extraarticular manifestations. Several TNFi are licensed for extraarticular manifestations, including plaque psoriasis (IFX, ETN, ADA), Crohn's disease (IFX, ADA), and ulcerative colitis (IFX, ADA, GOL)¹¹⁰. Treatment of uveitis with TNFi is off-label, but may influence drug choice. The LOE is I and the SOR is A for this recommendation.

Use of TNFi for the treatment of uveitis is currently off-label, and cost remains the largest barrier to implementation¹¹⁰.

Recommendation 22. There is no evidence that combining MTX with TNFi improves efficacy, but it may affect persistence in peripheral SpA. In AS, addition of MTX to IFX did not affect outcomes, infusion numbers, TNFi switching, or dosing^{111,112,113,114,115}. In PsA, RCT demonstrated clinical and radiographic efficacy of several TNFi regardless of concomitant MTX^{102,106,116,117,118}. However, observational studies and registries of PsA demonstrated that combining MTX with TNFi improved persistence^{119,120}. The LOE and SOR for MTX in addition to TNF for efficacy are I and A; for treatment persistence in peripheral SpA, II and B.

There are no barriers to implementation.

Recommendation 23. TNFi nonresponders may benefit from TNFi switching. To our knowledge, no RCT has studied TNFi switching in AS, but numerous observational studies, registries, and retrospective studies support switching^{121,122,123,124,125,126}. Switching has also been studied in PsA observational studies and registries^{127,128,129}. CZP has been found to be effective in patients with PsA who have previously failed TNFi¹⁰⁸. In overall SpA, response to second and third TNFi was high¹³⁰. The Spanish Registry of Adverse Events of Biological Therapies in Rheumatic Diseases study also showed response to switching, though there was less retention of the second agent¹³¹. This recommendation has a LOE II and SOR B.

Implementation may be limited because of therapy cost.

Other Biologic Agents

Recommendation 24. Consider rituximab (RTX) in axSpA when TNFi are contraindicated. RTX is a monoclonal antibody against CD20+ B cells. One trial demonstrated that established, TNF-naive patients with AS were able to achieve clinical response to RTX while TNFi failures were unresponsive¹³². A registry of RTX in SpA also demonstrated moderate efficacy in TNFi-naive subjects¹³³. Recommendation 24 has an LOE II and SOR B.

However, RTX is currently not approved for SpA treatment in Canada¹¹⁰. Cost is another barrier.

Recommendation 25. Consider ustekinumab (UST), a monoclonal antibody against interleukin 12/23, for SpA with concomitant moderate–severe psoriasis. The PSUMMIT-I RCT found significant improvements in clinical outcomes and good safety with UST¹³⁴. A

double-blind RCT of patients with PsA and $\geq 3\%$ body surface area psoriasis also showed that UST reduced arthritis, enthesitis, dactylitis, and skin lesions, and improved function¹³⁵. UST was also found to reduce progression of radiographic damage in PsA¹³⁶. The LOE and SOR for this recommendation are I and A. UST is approved for PsA treatment in Canada¹¹⁰.

Though UST has been approved, it does not appear on the provincial formulary universally. Cost is also an obstacle.

Recommendation 26. There is no evidence for the use of other biologics in SpA, including abatacept (ABA), tocilizumab (TCZ), and anakinra^{137,138,139,140,141,142,143,144,145,146,147,148}. Interestingly, a 6-month, randomized, double-blind, placebo-controlled study of ABA in PsA suggested that it may be effective at a dose of 10 mg/kg, potentially indicating a differential effect in peripheral versus axial disease¹³⁷. As more data about non-TNFi biologics continue to emerge, the authors anticipate ongoing rapid change in this area. Currently, the LOE and SOR for ABA, TCZ, and anakinra are II and B, I and A, and II and B, respectively.

There are no barriers to the implementation of this recommendation.

Surgery

Recommendation 27. Consider total hip arthroplasty (THA) in patients with pain, disability, and damage, regardless of age. THA in AS has been studied through registries and case series^{149,150}. Observational studies of THA in AS have shown good outcomes, even when performed at a young age^{151,152,153,154,155,156,157,158,159,160,161,162}. The LOE and SOR for this recommendation are II and B. No studies exist of THA in peripheral SpA (LOE IV, SOR D).

Barriers to implementation include long waiting lists and access to specialized surgical centers.

Recommendation 28. Studies of spinal surgical interventions in SpA are largely case series showing positive effects (LOE III, SOR C)^{163,164,165,166,167,168,169,170,171,172,173,174,175,176}. A detailed review of these surgical procedures is beyond the scope of this paper. Recommendation 28 has LOE III and SOR C.

The major barrier to the implementation of this recommendation is the limited access to specialized surgical centers.

Juvenile SpA

JSpA typically presents with more peripheral and enthesal involvement compared with adults¹⁷⁷. It includes several overlapping subtypes: juvenile ankylosing spondylitis (JAS), juvenile PsA, reactive arthritis, enteropathic arthritis, and undifferentiated disease called ERA¹⁷⁷. Currently, ERA is the most common form of SpA seen among children with

juvenile idiopathic arthritis (JIA)¹⁷⁷ and the recommendations will address this population specifically. Because of shared familial and genetic predispositions, JSpA(ERA) may be thought of as an on-a-continuum-of disease with adult SpA¹⁷⁷. Indeed, many adult rheumatologists in Canada will manage patients with JSpA(ERA) who have passed the age of 18. This section of the 2014 Update of the CRA/SPARCC Recommendations for the Management of SpA will address adaptations of the adult SpA recommendations that may be applied to JSpA(ERA).

Nonpharmacological

Recommendation 1. Physical activity is encouraged in JSpA(ERA). Though patients with JIA have reduced aerobic and anaerobic fitness^{178,179}, participation in exercise does not exacerbate disease¹⁸⁰. Single-blind RCT of exercise in JIA also showed improved function and quality of life^{181,182}. Note that these studies do not specifically assess exercise in JSpA (LOE I, SOR B).

There are no barriers to the implementation of this recommendation.

Recommendation 2. Peripheral arthritis and enthesitis involving the foot and ankle are common. Use of foot orthotics is supported by a randomized trial that may have included patients with ERA, but did not specifically address JSpA(ERA). The LOE is I and the SOR is B¹⁸³.

Implementation of this recommendation may be limited because of cost.

NSAID and Analgesics

Recommendation 3. Peripheral arthritis is more common in JSpA(ERA). Patients should be treated with a longer NSAID trial (1–2 mos; LOE IV, SOR D).

There are no barriers to the implementation of this recommendation.

Recommendation 4. Sacroiliitis in JSpA(ERA) can be managed with NSAID according to the adult axSpA recommendations. To our knowledge, no trials in JSpA(ERA) exist (LOE IV, SOR D).

There are no barriers to the implementation of this recommendation.

Corticosteroids

Recommendation 5. There are no modifications. Only 1 study specifically addresses JSpA¹⁸⁴. Most data are extrapolated from studies of JIA (LOE I, SOR B)^{185,186,187,188,189,190}.

DMARD

Recommendation 6. There are no modifications to the adult recommendations.

Only 2 RCT have assessed SSZ in a pediatric population. In patients with JAS or seronegative enthesopathy and arthropathy, SSZ did not improve primary outcomes, but

improved patient and physician assessments of disease activity¹⁹¹. A double-blind, placebo-controlled study of SSZ in juvenile chronic arthritis (including JSpA) demonstrated efficacy and safety in oligo- and polyarticular arthritis¹⁹². Longterm followup showed prolonged benefit¹⁹³. Chart reviews and open-label studies also support SSZ use^{194,195,196,197,198,199,200,201,202,203,204,205}.

There are no studies of MTX in JSpA(ERA). One double-blind placebo-controlled RCT of MTX in juvenile rheumatoid arthritis (JRA) showed improvements in joint pain, motion, and APR²⁰⁶. Two additional positive RCT exist in JIA^{207,208}, as do open-label and retrospective studies^{209,210,211,212,213}.

As with MTX, there are no studies of LEF in JSpA(ERA). An RCT of LEF versus MTX in polyarticular JRA showed that both produced improvement²¹⁴. An open-label study in JRA also demonstrated efficacy and durability²¹⁵ (LOE I, SOR A for SSZ; LOE III, SOR C for MTX and LEF).

Antibiotics

Recommendation 7. There are no trials of antibiotics in the treatment of JSpA(ERA). There are no modifications (LOE IV, SOR D).

TNF Inhibitors

Recommendation 8. TNFi are beneficial in JSpA(ERA) and should be prescribed according to predominantly axial or peripheral SpA recommendations. TNFi for JSpA(ERA) treatment include ETN, ADA, and IFX. There is only 1 TNFi RCT in JSpA that demonstrated significant improvements in joint count, ESR, MDGA, and patient global assessment²¹⁶. Open-label studies of IFX^{217,218,219} and ETN^{217,220} also show TNFi efficacy. Case reports/series of IFX^{221,222} and ETN²²³ also support TNFi use. A registry showed that ADA was effective in DMARD-resistant ERA²¹⁹. An RCT of ADA in ERA has also shown immediate and sustained efficacy²²⁴. Several studies have examined the effectiveness of TNFi in JIA (which may include ERA), but an extensive review is considered beyond this paper's scope. LOE I, SOR A for IFX and ADA in JSpA(ERA); LOE II, SOR B for ETN.

TNFi use in JSpA(ERA) has the same barriers to implementation as are present in adults.

Other Biologic Agents

Recommendation 9. To the best of our knowledge, other biologic agents in JSpA(ERA) have not been studied (LOE IV, SOR D).

Surgery

Recommendation 10. There are no specific modifications to the adult SpA recommendations with, to our knowledge, no studies found in JSpA(ERA). The LOE is IV and the SOR is D.

DISCUSSION

The 2014 Update on the CRA/SPARCC Treatment Recommendations for the Management of Spondyloarthritis was developed by a national working group using current literature containing 28 specific treatment recommendations. A treatment algorithm is proposed in Figure 1. Also included are 10 modifications for application to the JSpA(ERA) population. Of note, the majority of these recommendations are based upon evidence from studies of AS and PsA, but we are using these data to inform our recommendations for axial and peripheral SpA in general.

The intent of these recommendations is to inform Canadian rheumatologists, primary care physicians, internists and other healthcare providers, persons with SpA, insurance payers, government agencies, and formularies. It is recognized that each patient is unique and that recommendations cannot be blindly applied to all. Each treating physician should use these recommendations along with their clinical judgment and in partnership with their patients. Ideal SpA management is individualized and specific to each particular patient.

Many questions about SpA management remain unanswered, and barriers to the implementation of these recommendations must be addressed. As the field of SpA management and treatment evolves, updates will be needed.

ONLINE SUPPLEMENT

Supplementary data for this article are available online at jrheum.org.

REFERENCES

1. Rohekar A, Chan J, Tse SM, Haroon N, Chandran V, Bessette L, et al. 2014 Update on the Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada Treatment Recommendations for the Management of Spondyloarthritis. Part I: principles of the management of spondyloarthritis in Canada. *J Rheumatology* 2014;42:654-64.
2. van den Berg R, Baraliakos X, Braun J, van der Heijde D. First update of the current evidence for the management of ankylosing spondylitis with non-pharmacological treatment and non-biologic drugs: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. *Rheumatology* 2012;51:1388-96.
3. Dagfinrud H, Kvien TK, Hagen KB. The Cochrane review of physiotherapy interventions for ankylosing spondylitis. *J Rheumatol* 2005;32:1899-906.
4. Dagfinrud H, Halvorsen S, Vollestad NK, Niedermann K, Kvien TK, Hagen KB. Exercise programs in trials for patients with ankylosing spondylitis: do they really have the potential for effectiveness? *Arthritis Care Res* 2011;63:597-603.
5. Poddubnyy D, Haibel H, Listing J, Marker-Hermann E, Zeidler H, Braun J, et al. Cigarette smoking has a dose-dependent impact on progression of structural damage in the spine in patients with axial spondyloarthritis: results from the GERman SPondyloarthritis inception cohort (GESPIC). *Ann Rheum Dis* 2013;72:1430-2.
6. Haroon N, Inman RD, Learch TJ, Weisman MH, Lee M, Rahbar MH, et al. The impact of tumor necrosis factor alpha inhibitors on radiographic progression in ankylosing spondylitis. *Arthritis Rheum* 2013;65:2645-54.




Figure 1. Treatment algorithm for SpA. SpA: spondyloarthritis; NSAID: nonsteroidal antiinflammatory drugs; SI: sacroiliac; axSpA: axial SpA; DMARD: disease-modifying antirheumatic drugs; MTX: methotrexate; LEF: leflunomide; SSZ: sulfasalazine; TNFi: tumor necrosis factor inhibitors.

7. Chung HY, Machado P, van der Heijde D, D'Agostino MA, Dougados M. Smokers in early axial spondyloarthritis have earlier disease onset, more disease activity, inflammation and damage, and poorer function and health-related quality of life: results from the DESIR cohort. *Ann Rheum Dis* 2012;71:809-16.
8. Ward MM, Hendrey MR, Malley JD, Leach TJ, Davis JC Jr, Reveille JD, et al. Clinical and immunogenetic prognostic factors for radiographic severity in ankylosing spondylitis. *Arthritis Rheum* 2009;61:859-66.
9. Ward MM, Weisman MH, Davis JC Jr, Reveille JD. Risk factors for functional limitations in patients with long-standing ankylosing spondylitis. *Arthritis Rheum* 2005;53:710-7.
10. Kaan U, Ferda O. Evaluation of clinical activity and functional impairment in smokers with ankylosing spondylitis. *Rheumatol Int* 2005;25:357-60.
11. Doran MF, Brophy S, MacKay K, Taylor G, Calin A. Predictors of

- longterm outcome in ankylosing spondylitis. *J Rheumatol* 2003;30:316-20.
12. Ward MM. Predictors of the progression of functional disability in patients with ankylosing spondylitis. *J Rheumatol* 2002;29:1420-5.
 13. Aaverns HL, Oxtoby J, Taylor HG, Jones PW, Dziedzic K, Dawes PT. Smoking and outcome in ankylosing spondylitis. *Scand J Rheumatol* 1996;25:138-42.
 14. Bodur H, Ataman S, Rezvani A, Bugdayci DS, Cevik R, Birtane M, et al. Quality of life and related variables in patients with ankylosing spondylitis. *Qual Life Res* 2011;20:543-9.
 15. Matthey DL, Dawson SR, Healey EL, Packham JC. Relationship between smoking and patient-reported measures of disease outcome in ankylosing spondylitis. *J Rheumatol* 2011;38:2608-15.
 16. Tillett W, Jadon D, Shaddick G, Cavill C, Korendowych E, de Vries CS, et al. Smoking and delay to diagnosis are associated with poorer functional outcome in psoriatic arthritis. *Ann Rheum Dis* 2013;72:1358-61.
 17. van der Heijde D, Baraf HS, Ramos-Remus C, Calin A, Weaver AL, Schiff M, et al. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. *Arthritis Rheum* 2005;52:1205-15.
 18. Gossec L, van der Heijde D, Melian A, Krupa DA, James MK, Cavanaugh PF, et al. Efficacy of cyclo-oxygenase-2 inhibition by etoricoxib and naproxen on the axial manifestations of ankylosing spondylitis in the presence of peripheral arthritis. *Ann Rheum Dis* 2005;64:1563-7.
 19. Sieper J, Klopsch T, Richter M, Kapelle A, Rudwaleit M, Schwank S, et al. Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study. *Ann Rheum Dis* 2008;67:323-9.
 20. Cinar M, Dinc A, Simsek I, Erdem H, Koc B, Pay S, et al. Evaluation of the short-term efficacy of NSAIDs on patients with active ankylosing spondylitis in daily practice: A 3-month, longitudinal, observational study. *Rheumatol Int* 2010;30:331-40.
 21. Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos-Vargas R, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. *Ann Rheum Dis* 2009;68 Suppl 2:ii1-44.
 22. Escalas C, Trijau S, Dougados M. Evaluation of the treatment effect of NSAIDs/TNF blockers according to different domains in ankylosing spondylitis: results of a meta-analysis. *Rheumatology* 2010;49:1317-25.
 23. Benhamou M, Gossec L, Dougados M. Clinical relevance of C-reactive protein in ankylosing spondylitis and evaluation of the NSAIDs/coxibs' treatment effect on C-reactive protein. *Rheumatology* 2010;49:536-41.
 24. Wanders A, Heijde Dv, Landewé R, Béhier JM, Calin A, Olivieri I, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. *Arthritis Rheum* 2005;52:1756-65.
 25. Kroon F, Landewé R, Dougados M, van der Heijde D. Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. *Ann Rheum Dis* 2012;71:1623-9.
 26. Poddubnyy D, Rudwaleit M, Haibel H, Listing J, Marker-Hermann E, Zeidler H, et al. Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. *Ann Rheum Dis* 2012;71:1616-22.
 27. Song IH, Poddubnyy DA, Rudwaleit M, Sieper J. Benefits and risks of ankylosing spondylitis treatment with nonsteroidal antiinflammatory drugs. *Arthritis Rheum* 2008;58:929-38.
 28. Maugars Y, Mathis C, Vilon P, Prost A. Corticosteroid injection of the sacroiliac joint in patients with seronegative spondylarthropathy. *Arthritis Rheum* 1992;35:564-8.
 29. Luukkainen R, Nissilä M, Asikainen E, Sanila M, Lehtinen K, Alanaatu A, et al. Periarticular corticosteroid treatment of the sacroiliac joint in patients with seronegative spondylarthropathy. *Clin Exp Rheumatol* 1999;17:88-90.
 30. Maugars Y, Mathis C, Berthelot JM, Charlier C, Prost A. Assessment of the efficacy of sacroiliac corticosteroid injections in spondylarthropathies: a double-blind study. *Br J Rheumatol* 1996;35:767-70.
 31. Bollow M, Braun J, Taupitz M, Haberle J, Reibhauer BH, Paris S, et al. CT-guided intraarticular corticosteroid injection into the sacroiliac joints in patients with spondyloarthropathy: Indication and follow-up with contrast-enhanced MRI. *J Comput Assist Tomogr* 1996;20:512-21.
 32. Braun J, Bollow M, Seyrekbasan F, Haberle HJ, Eggens U, Mertz A, et al. Computed tomography guided corticosteroid injection of the sacroiliac joint in patients with spondyloarthropathy with sacroiliitis: clinical outcome and followup by dynamic magnetic resonance imaging. *J Rheumatol* 1996;23:659-64.
 33. Hanly JG, Mitchell M, MacMillan L, Mosher D, Sutton E. Efficacy of sacroiliac corticosteroid injections in patients with inflammatory spondyloarthropathy: results of a 6 month controlled study. *J Rheumatol* 2000;27:719-22.
 34. Karabacakoglu A, Karakose S, Ozerbil OM, Odev K. Fluoroscopy-guided intraarticular corticosteroid injection into the sacroiliac joints in patients with ankylosing spondylitis. *Acta Radiol* 2002;43:425-7.
 35. Dussault RG, Kaplan PA, Anderson MW. Fluoroscopy-guided sacroiliac joint injections. *Radiology* 2000;214:273-7.
 36. Eder L, Chandran V, Ueng J, Bhella S, Lee KA, Rahman P, et al. Predictors of response to intra-articular steroid injection in psoriatic arthritis. *Rheumatology* 2010;49:1367-73.
 37. Haibel H, Fendler C, Listing J, Callhoff J, Braun J, Sieper J. Efficacy of oral prednisolone in active ankylosing spondylitis: results of a double-blind, randomised, placebo-controlled short-term trial. *Ann Rheum Dis* 2014;73:243-6.
 38. Ejstrup L, Peters ND. Intravenous methylprednisolone pulse therapy in ankylosing spondylitis. *Dan Med Bull* 1985;32:231-3.
 39. Peters ND, Ejstrup L. Intravenous methylprednisolone pulse therapy in ankylosing spondylitis. *Scand J Rheumatol* 1992; 21:134-8.
 40. Zink A, Thiele K, Huscher D, Listing J, Sieper J, Krause A, et al. Healthcare and burden of disease in psoriatic arthritis. A comparison with rheumatoid arthritis and ankylosing spondylitis. *J Rheumatol* 2006;33:86-90.
 41. Chen J, Veras MM, Liu C, Lin J. Methotrexate for ankylosing spondylitis. *Cochrane Database Syst Rev* 2013;2:CD004524.
 42. Chen J, Liu C. Sulfasalazine for ankylosing spondylitis. *Cochrane Database Syst Rev* 2005;CD004800.
 43. Chen J, Liu C. Is sulfasalazine effective in ankylosing spondylitis? A systematic review of randomized controlled trials. *J Rheumatol* 2006;33:722-31.
 44. Steiman AJ, Pope JE, Thiessen-Philbrook H, Li L, Barnabe C, Kalache F, et al. Non-biologic disease-modifying antirheumatic drugs (DMARDs) improve pain in inflammatory arthritis (IA): a systematic literature review of randomized controlled trials. *Rheumatol Int* 2013;33:1105-20.
 45. Braun J, van der Horst-Bruinsma IE, Huang F, Burgos-Vargas R, Vlahos B, Koenig AS, et al. Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial. *Arthritis Rheum* 2011;63:1543-51.
 46. Song IH, Hermann K, Haibel H, Althoff CE, Listing J, Burmester G, et al. Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by

- whole-body MRI (ESTHER): a 48-week randomised controlled trial. *Ann Rheum Dis* 2011;70:590-6.
47. van der Heijde D, Braun J, Dougados M, Sieper J, Pedersen R, Szumski A, et al. Sensitivity and discriminatory ability of the ankylosing spondylitis disease activity score in patients treated with etanercept or sulphasalazine in the ASCEND trial. *Rheumatology* 2012;51:1894-905.
 48. van Denderen JC, van der Paardt M, Nurmohamed MT, de Ryck YM, Dijkmans BA, van der Horst-Bruinsma IE. Double blind, randomised, placebo controlled study of leflunomide in the treatment of active ankylosing spondylitis. *Ann Rheum Dis* 2005;64:1761-4.
 49. Haibel H, Rudwaleit M, Braun J, Sieper J. Six months open label trial of leflunomide in active ankylosing spondylitis. *Ann Rheum Dis* 2005;64:124-6.
 50. Ash Z, Gaujoux-Viala C, Gossec L, Hensor EM, FitzGerald O, Winthrop K, et al. A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. *Ann Rheum Dis* 2012; 71:319-26.
 51. Scarpa R, Peluso R, Atteno M, Manguso F, Spano A, Iervolino S, et al. The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: Results of a pilot randomised 6-month trial with methotrexate. *Clin Rheumatol* 2008;27:823-6.
 52. Black RL, O'Brien WM, Vanscott EJ, Auerbach R, Eisen AZ, Bunim JJ. Methotrexate therapy in psoriatic arthritis; double-blind study on 21 patients. *JAMA* 1964;189:743-7.
 53. Willkens RF, Williams HJ, Ward JR, Egger MJ, Reading JC, Clements PJ, et al. Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. *Arthritis Rheum* 1984;27:376-81.
 54. Abu-Shakra M, Gladman DD, Thorne JC, Long J, Gough J, Farewell VT. Longterm methotrexate therapy in psoriatic arthritis: clinical and radiological outcome. *J Rheumatol* 1995;22:241-5.
 55. Kingsley GH, Kowalczyk A, Taylor H, Ibrahim F, Packham JC, McHugh NJ, et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. *Rheumatology* 2012;51:1368-77.
 56. Rahman P, Gladman DD, Cook RJ, Zhou Y, Young G. The use of sulfasalazine in psoriatic arthritis: a clinic experience. *J Rheumatol* 1998;25:1957-61.
 57. Kaltwasser JP, Nash P, Gladman D, Rosen CF, Behrens F, Jones P, et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. *Arthritis Rheum* 2004;50:1939-50.
 58. Liang GC, Barr WG. Open trial of leflunomide for refractory psoriasis and psoriatic arthritis. *J Clin Rheumatol* 2001;7:366-70.
 59. Thami GP, Garg G. Leflunomide in psoriasis and psoriatic arthritis: a preliminary study. *Arch Dermatol* 2004;140:1288-9.
 60. Behrens F, Finkenwirth C, Pavelka K, Stolfa J, Sipek-Dolnicar A, Thaci D, et al. Leflunomide in psoriatic arthritis: results from a large European prospective observational study. *Arthritis Care Res* 2013;65:464-70.
 61. Barber CE, Kim J, Inman RD, Esdaile JM, James MT. Antibiotics for treatment of reactive arthritis: a systematic review and metaanalysis. *J Rheumatol* 2013;40:916-28.
 62. Carter JD, Espinoza LR, Inman RD, Sneed KB, Ricca LR, Vasey FB, et al. Combination antibiotics as a treatment for chronic chlamydia-induced reactive arthritis: a double-blind, placebo-controlled, prospective trial. *Arthritis Rheum* 2010;62:1298-307.
 63. Baraliakos X, van den Berg R, Braun J, van der Heijde D. Update of the literature review on treatment with biologics as a basis for the first update of the ASAS/EULAR management recommendations of ankylosing spondylitis. *Rheumatology* 2012;51:1378-87.
 64. Heldmann F, Brandt J, van der Horst-Bruinsma IE, Landewé R, Sieper J, Burmester GR, et al. The European ankylosing spondylitis infliximab cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximab. *Clin Exp Rheumatol* 2011;29:672-80.
 65. Baraliakos X, Haibel H, Listing J, Sieper J, Braun J. Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis. *Ann Rheum Dis* 2014;73:710-5.
 66. Saougou I, Markatseli TE, Voulgari PV, Drosos AA. Maintained clinical response of infliximab treatment in ankylosing spondylitis: a 6-year long-term study. *Joint Bone Spine* 2010;77:325-9.
 67. Konsta M, Sfrikakis PP, Bournia VK, Karras D, Iliopoulos A. Absence of radiographic progression of hip arthritis during infliximab treatment for ankylosing spondylitis. *Clin Rheumatol* 2013;32:1229-32.
 68. Tenga G, Goëb V, Lequerré T, Bacquet-Deschryver H, Daragon A, Pouplin S, et al. A 3 mg/kg starting dose of infliximab in active spondyloarthritis resistant to conventional treatments is efficient, safe and lowers costs. *Joint Bone Spine* 2011;78:50-5.
 69. Inman RD, Maksymowych WP; CANDLER Study Group. A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis. *J Rheumatol* 2010;37:1203-10.
 70. Maksymowych WP, Salonen D, Inman RD, Rahman P, Lambert RG; CANDLER Study Group. Low-dose infliximab (3 mg/kg) significantly reduces spinal inflammation on magnetic resonance imaging in patients with ankylosing spondylitis: a randomized placebo-controlled study. *J Rheumatol* 2010;37:1728-34.
 71. Mörck B, Pullerits R, Geijer M, Bremell T, Forsblad-d'Elia H. Infliximab dose reduction sustains the clinical treatment effect in active HLAB27 positive ankylosing spondylitis: a two-year pilot study. *Mediators Inflamm* 2013;2013:289845.
 72. Ertenli I, Ozer S, Kiraz S, Apras SB, Akdogan A, Karadag O, et al. Infliximab, a TNF- α antagonist treatment in patients with ankylosing spondylitis: the impact on depression, anxiety and quality of life level. *Rheumatol Int* 2012;32:323-30.
 73. Giardina AR, Ferrante A, Ciccio F, Impastato R, Miceli MC, Principato A, et al. A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis. *Rheumatol Int* 2010;30:1437-40.
 74. Sieper J, Lenaerts J, Wollenhaupt J, Rudwaleit M, Mazurov VI, Myasoutova L, et al. Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1. *Ann Rheum Dis* 2014;73:101-7.
 75. Song IH, Weiss A, Hermann KG, Haibel H, Althoff CE, Poddubnyy D, et al. Similar response rates in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis after 1 year of treatment with etanercept: Results from the ESTHER trial. *Ann Rheum Dis* 2013;72:823-5.
 76. Song IH, Althoff CE, Haibel H, Hermann KG, Poddubnyy D, Listing J, et al. Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial. *Ann Rheum Dis* 2012;71:1212-5.
 77. Song IH, Hermann KG, Haibel H, Althoff CE, Poddubnyy D, Listing J, et al. Relationship between active inflammatory lesions in the spine and sacroiliac joints and new development of chronic lesions on whole-body MRI in early axial spondyloarthritis: results of the ESTHER trial at week 48. *Ann Rheum Dis* 2011;70:1257-63.
 78. Lubrano E, Spadaro A, Marchesoni A, Olivieri I, Scarpa R, D'Angelo S, et al. The effectiveness of a biologic agent on axial manifestations of psoriatic arthritis. A twelve months observational

- study in a group of patients treated with etanercept. *Clin Exp Rheumatol* 2011;29:80-4.
79. Sieper J, van der Heijde D, Dougados M, Mease PJ, Maksymowych WP, Brown MA, et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). *Ann Rheum Dis* 2013;72:815-22.
 80. Haibel H, Heldmann F, Braun J, Listing J, Kupper H, Sieper J. Long-term efficacy of adalimumab after drug withdrawal and retreatment in patients with active non-radiographically evident axial spondyloarthritis who experience a flare. *Arthritis Rheum* 2013;65:2211-3.
 81. Sieper J, van der Heijde D, Dougados M, Brown LS, Lavie F, Pangan AL. Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis. *Ann Rheum Dis* 2012;71:700-6.
 82. Kimel M, Revicki D, Rao S, Fryback D, Feeny D, Harnam N, et al. Norms-based assessment of patient-reported outcomes associated with adalimumab monotherapy in patients with ankylosing spondylitis. *Clin Exp Rheumatol* 2011;29:624-32.
 83. Rudwaleit M, Gooch K, Michel B, Herold M, Thorner A, Wong R, et al. Adalimumab improves sleep and sleep quality in patients with active ankylosing spondylitis. *J Rheumatol* 2011;38:79-86.
 84. Maksymowych WP, Gooch KL, Wong RL, Kupper H, van der Heijde D. Impact of age, sex, physical function, health-related quality of life, and treatment with adalimumab on work status and work productivity of patients with ankylosing spondylitis. *J Rheumatol* 2010;37:385-92.
 85. Braun J, Rudwaleit M, Kary S, Kron M, Wong RL, Kupper H. Clinical manifestations and responsiveness to adalimumab are similar in patients with ankylosing spondylitis with and without concomitant psoriasis. *Rheumatology* 2010;49:1578-89.
 86. Rudwaleit M, Claudepierre P, Kron M, Kary S, Wong R, Kupper H. Effectiveness of adalimumab in treating patients with ankylosing spondylitis associated with enthesitis and peripheral arthritis. *Arthritis Res Ther* 2010;12:R43.
 87. Rudwaleit M, Van den Bosch F, Kron M, Kary S, Kupper H. Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy. *Arthritis Res Ther* 2010;12:R117.
 88. Kobayashi S, Harigai M, Mozaffarian N, Pangan AL, Sharma S, Brown LS, et al. A multicenter, open-label, efficacy, pharmacokinetic, and safety study of adalimumab in Japanese patients with ankylosing spondylitis. *Mod Rheumatol* 2012; 22:589-97.
 89. Huang F, Gu J, Zhu P, Bao C, Xu J, Xu H, et al. Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial. *Ann Rheum Dis* 2014;73:587-94.
 90. Inman RD, Davis JC Jr, Heijde Dv, Diekman L, Sieper J, Kim SI, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. *Arthritis Rheum* 2008; 58:3402-12.
 91. Braun J, Deodhar A, Inman RD, van der Heijde D, Mack M, Xu S, et al. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study. *Ann Rheum Dis* 2012;71:661-7.
 92. Braun J, Baraliakos X, Hermann KG, van der Heijde D, Inman RD, Deodhar AA, et al. Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo-controlled GO-RAISE study. *Ann Rheum Dis* 2012;71:878-84.
 93. van der Heijde D, Braun J, Deodhar A, Inman RD, Xu S, Mack ME, et al. Comparison of three enthesitis indices in a multicentre, randomized, placebo-controlled trial of golimumab in ankylosing spondylitis (GO-RAISE). *Rheumatology* 2013;52:321-5.
 94. Wagner C, Visvanathan S, Braun J, van der Heijde D, Deodhar A, Hsu B, et al. Serum markers associated with clinical improvement in patients with ankylosing spondylitis treated with golimumab. *Ann Rheum Dis* 2012;71:674-80.
 95. Landewé R, Braun J, Deodhar A, Dougados M, Maksymowych WP, Mease PJ, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. *Ann Rheum Dis* 2014;73:39-47.
 96. Brooks M. Medscape: FDA clears certolizumab (cimzia) for ankylosing spondylitis. [Internet. Accessed January 13, 2015.] Available from: www.medscape.com/viewarticle/812822
 97. Coates LC, Tillett W, Chandler D, Helliwell PS, Korendowych E, Kyle S, et al. The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics. *Rheumatology* 2013;52:1754-7.
 98. Paramarta JE, De Rycke L, Heijda TF, Ambarus CA, Vos K, Dinant HJ, et al. Efficacy and safety of adalimumab for the treatment of peripheral arthritis in spondyloarthritis patients without ankylosing spondylitis or psoriatic arthritis. *Ann Rheum Dis* 2013;72:1793-9.
 99. Marzo-Ortega H, McGonagle D, O'Connor P, Emery P. Efficacy of etanercept in the treatment of the enthesal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. *Arthritis Rheum* 2001;44:2112-7.
 100. Dougados M, van der Linden S, Leirisalo-Repo M, Huitfeldt B, Juhlin R, Veys E, et al. Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. *Arthritis Rheum* 1995;38:618-27.
 101. Gladman DD, Ziouzina O, Thavaneswaran A, Chandran V. Dactylitis in psoriatic arthritis: prevalence and response to therapy in the biologic era. *J Rheumatol* 2013;40:1357-9.
 102. Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. *Ann Rheum Dis* 2005;64:1150-7.
 103. Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). *Arthritis Rheum* 2005;52:1227-36.
 104. Gladman DD; ACCLAIM Study Investigators, Sampalis JS, Illouz O, Guérette B. Responses to adalimumab in patients with active psoriatic arthritis who have not adequately responded to prior therapy: effectiveness and safety results from an open-label study. *J Rheumatol* 2010;37:1898-906.
 105. Genovese MC, Mease PJ, Thomson GT, Kivitz AJ, Perdok RJ, Weinberg MA, et al. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. *J Rheumatol* 2007; 34:1040-50.
 106. Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. *Arthritis Rheum* 2009;60:976-86.
 107. Kavanaugh A, Mease P. Treatment of psoriatic arthritis with tumor necrosis factor inhibitors: longer-term outcomes including enthesitis and dactylitis with golimumab treatment in the longterm extension of a randomized, placebo-controlled study (GO-REVEAL). *J Rheumatol Suppl.* 2012 Jul;89:90-3.
 108. Mease PJ, Fleischmann R, Deodhar AA, Wollenhaupt J, Khraishi M, Kielar D, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a phase 3 double-blind randomised placebo-controlled study

- (RAPID-PsA). *Ann Rheum Dis* 2014;73:48-55.
109. Ritchlin CT, Kavanaugh A, Gladman DD, Mease PJ, Helliwell P, Boehncke WH, et al. Treatment recommendations for psoriatic arthritis. *Ann Rheum Dis* 2009;68:1387-94.
 110. Health Canada. [Internet. Accessed January 16, 2015.] Available from: www.hc-sc.gc.ca/index-eng.php
 111. Breban M, Ravaud P, Claudepierre P, Baron G, Henry YD, Hudry C, et al. Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment. *Arthritis Rheum* 2008;58:88-97.
 112. Li EK, Griffith JF, Lee VW, Wang YX, Li TK, Lee KK, et al. Short-term efficacy of combination methotrexate and infliximab in patients with ankylosing spondylitis: a clinical and magnetic resonance imaging correlation. *Rheumatology* 2008;47:1358-63.
 113. Marzo-Ortega H, McGonagle D, Jarrett S, Haugeberg G, Hensor E, O'Connor P, et al. Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study. *Ann Rheum Dis* 2005;64:1568-75.
 114. Ternant D, Mulleman D, Lauferon F, Vignault C, Ducourau E, Wendling D, et al. Influence of methotrexate on infliximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis. *Br J Clin Pharmacol* 2012;73:55-65.
 115. Mulleman D, Lauferon F, Wendling D, Ternant D, Ducourau E, Paintaud G, et al. Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study. *Arthritis Res Ther* 2011;13:R82.
 116. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. *Arthritis Rheum* 2004;50:2264-72.
 117. Gladman DD, Mease PJ, Ritchlin CT, Choy EH, Sharp JT, Ory PA, et al. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. *Arthritis Rheum* 2007;56:476-88.
 118. Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. *Arthritis Rheum* 2005;52:3279-89.
 119. Heiberg MS, Koldingsnes W, Mikkelsen K, Rodevand E, Kaufmann C, Mowinckel P, et al. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. *Arthritis Rheum* 2008;59:234-40.
 120. Kristensen LE, Gülfe A, Saxne T, Geborek P. Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register. *Ann Rheum Dis* 2008;67:364-9.
 121. Glinborg B, Østergaard M, Krogh NS, Tarp U, Manilo N, Loft AG, et al. Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry. *Ann Rheum Dis* 2013;72:1149-55.
 122. Lie E, van der Heijde D, Uhlig T, Mikkelsen K, Rodevand E, Koldingsnes W, et al. Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register. *Ann Rheum Dis* 2011;70:157-63.
 123. Coates LC, Cawkwell LS, Ng NW, Bennett AN, Bryer DJ, Fraser AD, et al. Real life experience confirms sustained response to long-term biologics and switching in ankylosing spondylitis. *Rheumatology* 2008;47:897-900.
 124. Dadoun S, Geri G, Paternotte S, Dougados M, Gossec L. Switching between tumour necrosis factor blockers in spondyloarthritis: a retrospective monocentre study of 222 patients. *Clin Exp Rheumatol* 2011;29:1010-3.
 125. Spadaro A, Lubrano E, Marchesoni A, D'Angelo S, Ramonda R, Addimanda O, et al. Remission in ankylosing spondylitis treated with anti-TNF- α drugs: a national multicentre study. *Rheumatology* 2013;52:1914-9.
 126. Cantini F, Niccoli L, Benucci M, Chindamo D, Nannini C, Olivieri I, et al. Switching from infliximab to once-weekly administration of 50 mg etanercept in resistant or intolerant patients with ankylosing spondylitis: results of a fifty-four-week study. *Arthritis Rheum* 2006;55:812-6.
 127. Glinborg B, Østergaard M, Krogh NS, Andersen MD, Tarp U, Loft AG, et al. Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry. *Arthritis Rheum* 2013;65:1213-23.
 128. Saad AA, Ashcroft DM, Watson KD, Hyrich KL, Noyce PR, Symmons DP, et al. Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. *Arthritis Res Ther* 2009;11:R52.
 129. Fagerli KM, Lie E, van der Heijde D, Heiberg MS, Kalstad S, Rodevand E, et al. Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study. *Ann Rheum Dis* 2013;72:1840-4.
 130. Paccou J, Solau-Gervais E, Houvenagel E, Salleron J, Luraschi H, Philippe P, et al. Efficacy in current practice of switching between anti-tumour necrosis factor- α agents in spondyloarthropathies. *Rheumatology* 2011;50:714-20.
 131. Gomez-Reino JJ, Carmona L; BIOBADASER Group. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. *Arthritis Res Ther* 2006;8:R29.
 132. Song IH, Heldmann F, Rudwaleit M, Listing J, Appel H, Braun J, et al. Different response to rituximab in tumor necrosis factor blocker-naïve patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial. *Arthritis Rheum* 2010;62:1290-7.
 133. Wendling D, Dougados M, Berenbaum F, Brocq O, Schaeferbeke T, Mazieres B, et al. Rituximab treatment for spondyloarthritis. A nationwide series: data from the AIR registry of the French Society of Rheumatology. *J Rheumatol* 2012;39:2327-31.
 134. McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C, et al; PSUMMIT 1 Study Group. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. *Lancet* 2013;382:780-9.
 135. Kavanaugh A, Menter A, Mendelsohn A, Shen YK, Lee S, Gottlieb AB. Effect of ustekinumab on physical function and health-related quality of life in patients with psoriatic arthritis: a randomized, placebo-controlled, phase II trial. *Curr Med Res Opin* 2010;26:2385-92.
 136. Kavanaugh A, Ritchlin C, Rahman P, Puig L, Gottlieb AB, Li S, et al; PSUMMIT-1 and 2 Study Groups. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. *Ann Rheum Dis* 2014;73:1000-6.
 137. Song IH, Heldmann F, Rudwaleit M, Haibel H, Weiss A, Braun J, et al. Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study. *Ann Rheum Dis* 2011;70:1108-10.
 138. Lekpa FK, Farrenq V, Canoui-Poitaine F, Paul M, Chevalier X, Bruckert R, et al. Lack of efficacy of abatacept in axial spondyloarthropathies refractory to tumor-necrosis-factor inhibition.

- Joint Bone Spine 2012;79:47-50.
139. Mease P, Genovese MC, Gladstein G, Kivitz AJ, Ritchlin C, Tak PP, et al. Abatacept in the treatment of patients with psoriatic arthritis: Results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. *Arthritis Rheum* 2011;63:939-48.
 140. Sieper J, Porter-Brown B, Thompson L, Harari O, Dougados M. Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials. *Ann Rheum Dis* 2014;73:95-100.
 141. Cohen JD, Ferreira R, Jorgensen C. Ankylosing spondylitis refractory to tumor necrosis factor blockade responds to tocilizumab. *J Rheumatol* 2011;38:1527.
 142. Henes JC, Horger M, Guenaydin I, Kanz L, Koetter I. Mixed response to tocilizumab for ankylosing spondylitis. *Ann Rheum Dis* 2010;69:2217-8.
 143. Hughes M, Chinoy H. Successful use of tocilizumab in a patient with psoriatic arthritis. *Rheumatology* 2013;52:1728-9.
 144. Ogata A, Umegaki N, Katayama I, Kumanogoh A, Tanaka T. Psoriatic arthritis in two patients with an inadequate response to treatment with tocilizumab. *Joint Bone Spine* 2012;79:85-7.
 145. Tanaka T, Kuwahara Y, Shima Y, Hirano T, Kawai M, Ogawa M, et al. Successful treatment of reactive arthritis with a humanized anti-interleukin-6 receptor antibody, tocilizumab. *Arthritis Rheum* 2009;61:1762-4.
 146. Tan AL, Marzo-Ortega H, O'Connor P, Fraser A, Emery P, McGonagle D. Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study. *Ann Rheum Dis* 2004;63:1041-5.
 147. Bennett AN, Tan AL, Coates LC, Emery P, Marzo-Ortega H, McGonagle D. Sustained response to anakinra in ankylosing spondylitis. *Rheumatology* 2008;47:223-4.
 148. Haibel H, Rudwaleit M, Listing J, Sieper J. Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. *Ann Rheum Dis* 2005;64:296-8.
 149. Vander Cruyssen B, Muñoz-Gomariz E, Font P, Mulero J, de Vlam K, Boonen A, et al. Hip involvement in ankylosing spondylitis: epidemiology and risk factors associated with hip replacement surgery. *Rheumatology* 2010;49:73-81.
 150. Burki V, Gossec L, Payet J, Durnez A, Elhai M, Fabreguet I, et al. Prevalence and characteristics of hip involvement in spondyloarthritis: a single-centre observational study of 275 patients. *Clin Exp Rheumatol* 2012;30:481-6.
 151. Tang WM, Chiu KY. Primary total hip arthroplasty in patients with ankylosing spondylitis. *J Arthroplasty* 2000;15:52-8.
 152. Sweeney S, Gupta R, Taylor G, Calin A. Total hip arthroplasty in ankylosing spondylitis: outcome in 340 patients. *J Rheumatol* 2001;28:1862-6.
 153. Bhan S, Eachempati KK, Malhotra R. Primary cementless total hip arthroplasty for bony ankylosis in patients with ankylosing spondylitis. *J Arthroplasty* 2008;23:859-66.
 154. Joshi AB, Markovic L, Hardinge K, Murphy JC. Total hip arthroplasty in ankylosing spondylitis: an analysis of 181 hips. *J Arthroplasty* 2002;17:427-33.
 155. Lehtimäki MY, Lehto MU, Kautiainen H, Lehtinen K, Hamalainen MM. Charnley total hip arthroplasty in ankylosing spondylitis: survivorship analysis of 76 patients followed for 8-28 years. *Acta Orthop Scand* 2001;72:233-6.
 156. Sochart DH, Porter ML. Long-term results of total hip replacement in young patients who had ankylosing spondylitis. Eighteen to thirty-year results with survivorship analysis. *J Bone Joint Surg Am* 1997;79:1181-9.
 157. Brinker MR, Rosenberg AG, Kull L, Cox DD. Primary noncemented total hip arthroplasty in patients with ankylosing spondylitis. Clinical and radiographic results at an average follow-up period of 6 years. *J Arthroplasty* 1996;11:802-12.
 158. Shih LY, Chen TH, Lo WH, Yang DJ. Total hip arthroplasty in patients with ankylosing spondylitis: longterm followup. *J Rheumatol* 1995;22:1704-9.
 159. Walker LG, Sledge CB. Total hip arthroplasty in ankylosing spondylitis. *Clin Orthop Relat Res* 1991:198-204.
 160. Kilgus DJ, Namba RS, Gorek JE, Cracchiolo A 3rd, Amstutz HC. Total hip replacement for patients who have ankylosing spondylitis. The importance of the formation of heterotopic bone and of the durability of fixation of cemented components. *J Bone Joint Surg Am* 1990;72:834-9.
 161. Calin A, Elswood J. The outcome of 138 total hip replacements and 12 revisions in ankylosing spondylitis: high success rate after a mean followup of 7.5 years. *J Rheumatol* 1989;16:955-8.
 162. Sundaram NA, Murphy JC. Heterotopic bone formation following total hip arthroplasty in ankylosing spondylitis. *Clin Orthop Relat Res* 1986:223-6.
 163. Wang Y, Zhang Y, Mao K, Zhang X, Wang Z, Zheng G, et al. Transpedicular bivertebrae wedge osteotomy and discectomy in lumbar spine for severe ankylosing spondylitis. *J Spinal Disord Tech* 2010;23:186-91.
 164. Belanger TA, Milam RA 4th, Roh JS, Bohlman HH. Cervicothoracic extension osteotomy for chin-on-chest deformity in ankylosing spondylitis. *J Bone Joint Surg Am* 2005;87:1732-8.
 165. Chang KW, Chen HC, Chen YY, Lin CC, Hsu HL, Cai YH. Sagittal translation in opening wedge osteotomy for the correction of thoracolumbar kyphotic deformity in ankylosing spondylitis. *Spine* 2006;31:1137-42.
 166. Kim KT, Suk KS, Cho YJ, Hong GP, Park BJ. Clinical outcome results of pedicle subtraction osteotomy in ankylosing spondylitis with kyphotic deformity. *Spine* 2002;27:612-8.
 167. Simmons ED, DiStefano RJ, Zheng Y, Simmons EH. Thirty-six years experience of cervical extension osteotomy in ankylosing spondylitis: techniques and outcomes. *Spine* 2006;31:3006-12.
 168. Qian BP, Wang XH, Qiu Y, Wang B, Zhu ZZ, Jiang J, et al. The influence of closing-opening wedge osteotomy on sagittal balance in thoracolumbar kyphosis secondary to ankylosing spondylitis: a comparison with closing wedge osteotomy. *Spine* 2012;37:1415-23.
 169. Brox JI, Helle A, Sorensen R, Gunderson R, Riise R, Reikeras O. Functional outcome after lumbar closing wedge osteotomy in ankylosing spondylitis. *Int Orthop* 2009;33:1049-53.
 170. Weale AE, Marsh CH, Yeoman PM. Secure fixation of lumbar osteotomy. Surgical experience with 50 patients. *Clin Orthop Relat Res* 1995:216-22.
 171. van Royen BJ, Slot GH. Closing-wedge posterior osteotomy for ankylosing spondylitis. Partial corporectomy and transpedicular fixation in 22 cases. *J Bone Joint Surg Br* 1995;77:117-21.
 172. Hehne HJ, Zielke K, Bohm H. Polysegmental lumbar osteotomies and transpedicled fixation for correction of long-curved kyphotic deformities in ankylosing spondylitis. Report on 177 cases. *Clin Orthop Relat Res* 1990:49-55.
 173. Min K, Hahn F, Leonardi M. Lumbar spinal osteotomy for kyphosis in ankylosing spondylitis: the significance of the whole body kyphosis angle. *J Spinal Disord Tech* 2007;20:149-53.
 174. Chang KW, Chen YY, Lin CC, Hsu HL, Pai KC. Closing wedge osteotomy versus opening wedge osteotomy in ankylosing spondylitis with thoracolumbar kyphotic deformity. *Spine* 2005;30:1584-93.
 175. Kim KT, Lee SH, Suk KS, Lee JH, Im YJ. Spinal pseudarthrosis in advanced ankylosing spondylitis with sagittal plane deformity: clinical characteristics and outcome analysis. *Spine* 2007; 32:1641-7.
 176. Chang KW, Tu MY, Huang HH, Chen HC, Chen YY, Lin CC. Posterior correction and fixation without anterior fusion for pseudoarthrosis with kyphotic deformity in ankylosing spondylitis.

- Spine 2006;31:E408-13.
177. Tse SM, Burgos-Vargas R, Colbert RA. Juvenile spondyloarthritis treatment recommendations. *Am J Med Sci* 2012;343:367-70.
 178. van Brussel M, Lelieveld OT, van der Net J, Engelbert RH, Helders PJ, Takken T. Aerobic and anaerobic exercise capacity in children with juvenile idiopathic arthritis. *Arthritis Rheum* 2007;57:891-7.
 179. Lelieveld OT, van Brussel M, Takken T, van Weert E, van Leeuwen MA, Armbrust W. Aerobic and anaerobic exercise capacity in adolescents with juvenile idiopathic arthritis. *Arthritis Rheum* 2007;57:898-904.
 180. Takken T, Van Brussel M, Engelbert RH, Van Der Net J, Kuis W, Helders PJ. Exercise therapy in juvenile idiopathic arthritis: a Cochrane review. *Eur J Phys Rehabil Med* 2008;44:287-97.
 181. Taracki E, Yeldan I, Baydogan SN, Olgar S, Kasapcopur O. Efficacy of a land-based home exercise programme for patients with juvenile idiopathic arthritis: a randomized, controlled, single-blind study. *J Rehabil Med* 2012;44:962-7.
 182. Singh-Grewal D, Schneiderman-Walker J, Wright V, Bar-Or O, Beyene J, Selvadurai H, et al. The effects of vigorous exercise training on physical function in children with arthritis: a randomized, controlled, single-blinded trial. *Arthritis Rheum* 2007;57:1202-10.
 183. Powell M, Seid M, Szer IS. Efficacy of custom foot orthotics in improving pain and functional status in children with juvenile idiopathic arthritis: a randomized trial. *J Rheumatol* 2005;32:943-50.
 184. Fischer T, Biedermann T, Hermann KG, Diekmann F, Braun J, Hamm B, et al. [Sacroiliitis in children with spondyloarthropathy: therapeutic effect of CT-guided intra-articular corticosteroid injection]. [Article in German] *Rofo* 2003;175:814-21.
 185. Papadopoulou C, Kostik M, Gonzalez-Fernandez MI, Bohm M, Nieto-Gonzalez JC, Pistorio A, et al. Delineating the role of multiple intraarticular corticosteroid injections in the management of juvenile idiopathic arthritis in the biologic era. *Arthritis Care Res* 2013;65:1112-20.
 186. Young CM, Shiels WE 2nd, Coley BD, Hogan MJ, Murakami JW, Jones K, et al. Ultrasound-guided corticosteroid injection therapy for juvenile idiopathic arthritis: 12-year care experience. *Pediatr Radiol* 2012;42:1481-9.
 187. Habibi S, Ellis J, Strike H, Ramanan AV. Safety and efficacy of IUS-guided CS injection into temporomandibular joints in children with active JIA. *Rheumatology* 2012;51:874-7.
 188. Ringold S, Torgerson TR, Egbert MA, Wallace CA. Intraarticular corticosteroid injections of the temporomandibular joint in juvenile idiopathic arthritis. *J Rheumatol* 2008;35:1157-64.
 189. Cahill AM, Cho SS, Baskin KM, Beukelman T, Cron RQ, Kaye RD, et al. Benefit of fluoroscopically guided intraarticular, long-acting corticosteroid injection for subtalar arthritis in juvenile idiopathic arthritis. *Pediatr Radiol* 2007;37:544-8.
 190. Ravelli A, Manzoni SM, Viola S, Pistorio A, Ruperto N, Martini A. Factors affecting the efficacy of intraarticular corticosteroid injection of knees in juvenile idiopathic arthritis. *J Rheumatol* 2001;28:2100-2.
 191. Burgos-Vargas R, Vázquez-Mellado J, Pacheco-Tena C, Hernández-Garduño A, Goycochea-Robles MV. A 26 week randomised, double blind, placebo controlled exploratory study of sulfasalazine in juvenile onset spondyloarthropathies. *Ann Rheum Dis* 2002;61:941-2.
 192. van Rossum MA, Fiselier TJ, Franssen MJ, Zwinderman AH, ten Cate R, van Suijlekom-Smit LW, et al. Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, double-blind, placebo-controlled, multicenter study. Dutch Juvenile Chronic Arthritis Study Group. *Arthritis Rheum* 1998;41:808-16.
 193. van Rossum MA, van Soesbergen RM, Boers M, Zwinderman AH, Fiselier TJ, Franssen MJ, et al. Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment. *Ann Rheum Dis* 2007;66:1518-24.
 194. Huang JL, Chen LC. Sulphasalazine in the treatment of children with chronic arthritis. *Clin Rheumatol* 1998;17:359-63.
 195. Imundo LF, Jacobs JC. Sulfasalazine therapy for juvenile rheumatoid arthritis. *J Rheumatol* 1996;23:360-6.
 196. Job-Deslandre C, Menkes CJ. [Treatment of juvenile spondyloarthropathies with sulfasalazine]. [Article in French] *Rev Rhum Ed Fr* 1993;60:489-91.
 197. Suschke HJ. [Treatment of juvenile spondylarthritis and reactive arthritis with sulfasalazine]. [Article in German] *Monatsschr Kinderheilkd* 1992;140:658-60.
 198. Chen CC, Lin YT, Yang YH, Chiang BL. Sulfasalazine therapy for juvenile rheumatoid arthritis. *J Formos Med Assoc* 2002;101:110-6.
 199. Brooks CD. Sulfasalazine for the management of juvenile rheumatoid arthritis. *J Rheumatol* 2001;28:845-53.
 200. Varbanova BB, Dyankov ED. Sulphasalazine. An alternative drug for second-line treatment of juvenile chronic arthritis. *Adv Exp Med Biol* 1999;455:331-6.
 201. Gedalia A, Barash J, Press J, Buskila D. Sulphasalazine in the treatment of pauciarticular-onset juvenile chronic arthritis. *Clin Rheumatol* 1993;12:511-4.
 202. Hoza J, Kadlecová T, Němcová D, Havelka S. Sulphasalazine and Delagil—a comparative study in patients with juvenile chronic arthritis. *Acta Univ Carol Med* 1991;37:80-3.
 203. Joos R, Veys EM, Mielants H, van Werveke S, Goemaere S. Sulfasalazine treatment in juvenile chronic arthritis: An open study. *J Rheumatol* 1991;18:880-4.
 204. Ansell BM, Hall MA, Loftus JK, Woo P, Neumann V, Harvey A, et al. A multicentre pilot study of sulphasalazine in juvenile chronic arthritis. *Clin Exp Rheumatol* 1991;9:201-3.
 205. Ozdogan H, Turunc M, Deringol B, Yurdakul S, Yazici H. Sulphasalazine in the treatment of juvenile rheumatoid arthritis: a preliminary open trial. *J Rheumatol* 1986;13:124-5.
 206. Giannini EH, Brewer EJ, Kuzmina N, Shaikov A, Maximov A, Vorontsov I, et al. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children's Study Group. *N Engl J Med* 1992;326:1043-9.
 207. Ruperto N, Murray KJ, Gerloni V, Wulffraat N, de Oliveira SK, Falcini F, et al. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. *Arthritis Rheum* 2004;50:2191-201.
 208. Woo P, Southwood TR, Prieur AM, Dore CJ, Grainger J, David J, et al. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. *Arthritis Rheum* 2000;43:1849-57.
 209. Klein A, Kaul I, Foeldvari I, Ganser G, Urban A, Horneff G. Efficacy and safety of oral and parenteral methotrexate therapy in children with juvenile idiopathic arthritis: an observational study with patients from the German Methotrexate Registry. *Arthritis Care Res* 2012;64:1349-56.
 210. Céspedes-Cruz A, Gutiérrez-Suárez R, Pistorio A, Ravelli A, Loy A, Murray KJ, et al. Methotrexate improves the health-related quality of life of children with juvenile idiopathic arthritis. *Ann Rheum Dis* 2008;67:309-14.
 211. Brik R, Gepstein V, Berkovitz D. Low-dose methotrexate treatment for oligoarticular juvenile idiopathic arthritis nonresponsive to intra-articular corticosteroids. *Clin Rheumatol* 2005;24:612-4.
 212. Reiff A, Shaham B, Wood BP, Bernstein BH, Stanley P, Szer IS. High dose methotrexate in the treatment of refractory juvenile rheumatoid arthritis. *Clin Exp Rheumatol* 1995;13:113-8.
 213. Halle F, Prieur AM. Evaluation of methotrexate in the treatment of

- juvenile chronic arthritis according to the subtype. *Clin Exp Rheumatol* 1991;9:297-302.
214. Silverman E, Mouy R, Spiegel L, Jung LK, Saurenmann RK, Lahdenne P, et al. Leflunomide or methotrexate for juvenile rheumatoid arthritis. *N Engl J Med* 2005;352:1655-66.
215. Silverman E, Spiegel L, Hawkins D, Petty R, Goldsmith D, Schanberg L, et al. Long-term open-label preliminary study of the safety and efficacy of leflunomide in patients with polyarticular-course juvenile rheumatoid arthritis. *Arthritis Rheum* 2005;52:554-62.
216. Burgos-Vargas R, Gutierrez-Suarez C. Efficacy, safety, and tolerability of infliximab in juvenile-onset spondyloarthropathies (JO-SpA): results of a three-month, randomized, double-blind, placebo-controlled trial phase. *Arthritis Rheum* 2007;56:S319.
217. Tse SM, Burgos-Vargas R, Laxer RM. Anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondylarthropathy. *Arthritis Rheum* 2005;52:2103-8.
218. Sulpice M, Deslandre CJ, Quartier P. Efficacy and safety of TNFalpha antagonist therapy in patients with juvenile spondyloarthropathies. *Joint Bone Spine* 2009;76:24-7.
219. Otten MH, Prince FH, Twilt M, Ten Cate R, Armbrust W, Hoppenreijns EP, et al. Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis—data from the Dutch arthritis and biologicals in children register, 1999-2010. *J Rheumatol* 2011;38:2258-63.
220. Henrickson M, Reiff A. Prolonged efficacy of etanercept in refractory enthesitis-related arthritis. *J Rheumatol* 2004;31:2055-61.
221. Burgos-Vargas R. A case of childhood-onset ankylosing spondylitis: diagnosis and treatment. *Nat Clin Pract Rheumatol* 2009;5:52-7.
222. Schmeling H, Horneff G. Infliximab in two patients with juvenile ankylosing spondylitis. *Rheumatol Int* 2004;24:173-6.
223. Tse SM, Laxer RM, Babyn PS, Doria AS. Radiologic improvement of juvenile idiopathic arthritis-enthesitis-related arthritis following anti-tumor necrosis factor-alpha blockade with etanercept. *J Rheumatol* 2006;33:1186-8.
224. Burgos-Vargas R, Tse SM, Horneff G, Pangan AL, Unnebrink K, Anderson JK. A3: efficacy and safety of adalimumab in pediatric patients with enthesitis related arthritis. *Arthritis Rheumatol* 2014;66 Suppl 11:S4.